Dynamic modeling of chronic myeloid leukemia response to bcr-abl1 tyrosine kinase inhibitors

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-PAA-013
• By: NOH, Hayeon (College of Pharmacy, Yonsei University, Department of Pharmacy, Incheon, Korea, Republic Of)
• Co-author(s): Hayeon Noh: Department of Pharmacy, College of Pharmacy, Yonsei University, Incheon, Korea, Republic Of
  Soo-Young Choi: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
  Hye-Young Song: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
  Soo-Hyun Kim: Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
  Su Young Jung: Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of;, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of
  Seungwon Yang: Department of Pharmacy, College of Pharmacy, Yonsei University, Incheon, Korea, Republic Of
  Won-Sik Lee: Department of Internal Medicine, Inje University College of Medicine, Inje University Busan Paik Hospital, Busan, Korea, Republic Of
  Hyeong-Joon Kim: Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic Of
  Jee Hyun Kong: Department of Hematology-Oncology, Wonju College of Medicine, Yonsei University, Wonju, Korea, Republic Of
  Hawk Kim: Department of Hematology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic Of
  Young Rok Do: Division of Hematology-Oncology, Keimyung University, School of Medicine, Keimyung University Hospital, Daegu, Korea, Republic Of
  Jae-Yong Kwak: Division of Hematology-Oncology, Chonbuk National University Medical School, Chonbuk National University Hospital, Jeonju, Korea, Republic Of
  Sukjoong Oh: Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Sungkyunkwan University, Kangbuk Samsung Hospital, Seoul, Korea, Republic Of
  Sung Hyun Kim: Department of Internal Medicine, Dong-A University College of Medicine, Dong-A University Hospital, Busan, Korea, Republic Of
  Jeong-A Kim: Department of Hematology, The Catholic University of Korea, St. Vincent’s Hospital, Suwon, Korea, Republic Of
  Dae Young Zang: Department of Internal Medicine, Hallym University College of Medicine, Hallym University Hospital, Anyang, Korea, Republic Of
  Yeung-Chul Mun: Department of Hematology, School of Medicine, Ewha Womans University, Ewha Womans University Hospital, Seoul, Korea, Republic Of
  Young-Woong Won: Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University College of Medicine, Hanyang University Guri Hospital, Guri, Korea, Republic Of
  Sung-Eun Lee: Department of Hematology, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
  Dong-Wook Kim: Department of Hematology, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic Of
  Jangik Lee: Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea, Republic Of;, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea, Republic Of
  
• Abstract:

  Background

  A BCR-ABL1 transcript level at 3 months after the initiation of imatinib has shown to predict the long-term clinical outcomes in patients with chronic myeloid leukemia in chronic phase (CP-CML). The levels obtained earlier than 3 months may also have a similar prognostic significance.

  Purpose

  To assess the value of the BCR-ABL1 transcript..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login